The attractive value proposition for our compound is: NeuMedics authored and was issued a patent for NM108 and it’s derivatives. It … Read More...

Neumedics compounds are patented and tested to confirm: NeuMedics central hypothesis is that … Continue Reading…
Diabetic Macular Edema (DME) DME is caused when fluid accumulates in the macula. It can develop … Continue Reading…
NM108 NeuMedics wrote and filed the patent for NM108 (8338477 issued December 2012 for NM108 and … Continue Reading…
The attractive value proposition for our compound is: NeuMedics authored and was issued a patent for NM108 and it’s derivatives. It … Read More...
Of the 3 currently accepted approaches for the treatment of DME: 1) focal laser 2) steroids, and 3) anti-VEGF, none are optimal, none fully … Read More...
NeuMedics is actively listed on crowd funding sites, Healthios, Gust, and Angel MD. Proceeds from these sources will be used to advance … Read More...